Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, FibroGen Inc’s stock clocked out at $0.32, down -1.09% from its previous closing price of $0.32. In other words, the price has decreased by -$1.09 from its previous closing price. On the day, 0.56 million shares were traded.
Ratios:
To gain a deeper understanding of FGEN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.98 and its Current Ratio is at 2.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on August 08, 2023, Downgraded its rating to Underperform and sets its target price to $2 from $4 previously.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 24 ’25 when Wettig Thane bought 145,000 shares for $0.35 per share. The transaction valued at 50,663 led to the insider holds 543,329 shares of the business.
Schoeneck James A bought 250,000 shares of FGEN for $88,000 on Mar 20 ’25. The Director now owns 323,722 shares after completing the transaction at $0.35 per share. On Mar 21 ’25, another insider, Schoeneck James A, who serves as the Director of the company, bought 50,000 shares for $0.34 each. As a result, the insider paid 17,040 and bolstered with 373,722 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.31.
Stock Price History:
Over the past 52 weeks, FGEN has reached a high of $1.53, while it has fallen to a 52-week low of $0.18. The 50-Day Moving Average of the stock is 2.06%, while the 200-Day Moving Average is calculated to be -19.52%.
Shares Statistics:
A total of 101.04M shares are outstanding, with a floating share count of 94.08M. Insiders hold about 6.90% of the company’s shares, while institutions hold 32.67% stake in the company.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 2.0 analysts currently analyzing and rating the stock of FibroGen Inc (FGEN).The consensus estimate for the next quarter is -$0.09, with high estimates of $0.03 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.14 and -$0.83 for the fiscal current year, implying an average EPS of -$0.49. EPS for the following year is -$0.73, with 2.0 analysts recommending between -$0.58 and -$0.87.
Revenue Estimates
In the current quarter, 2 analysts expect revenue to total $2.88M. It ranges from a high estimate of $3.75M to a low estimate of $2M. As of the current estimate, FibroGen Inc’s year-ago sales were $50.64MFor the next quarter, 2 analysts are estimating revenue of $2.9M. There is a high estimate of $3.8M for the next quarter, whereas the lowest estimate is $2M.
A total of 2 analysts have provided revenue estimates for FGEN’s current fiscal year. The highest revenue estimate was $12.7M, while the lowest revenue estimate was $7.3M, resulting in an average revenue estimate of $10M. In the same quarter a year ago, actual revenue was $203.28MBased on 2 analysts’ estimates, the company’s revenue will be $9.6M in the next fiscal year. The high estimate is $13.2M and the low estimate is $6M.
